Lifeboat Foundation

The technology behind the quantum computers of the future is fast developing, with several different approaches in progress. Many of the strategies, or “blueprints,” for quantum computers rely on atoms or artificial atom-like electrical circuits. In a new theoretical study in the journal Physical Review X, a group of physicists at Caltech demonstrates the benefits of a lesser-studied approach that relies not on atoms but molecules.

“In the quantum world, we have several blueprints on the table and we are simultaneously improving all of them,” says lead author Victor Albert, the Lee A. DuBridge Postdoctoral Scholar in Theoretical Physics. “People have been thinking about using molecules to encode information since 2001, but now we are showing how molecules, which are more complex than atoms, could lead to fewer errors in quantum computing.”

At the heart of quantum computers are what are known as qubits. These are similar to the bits in classical computers, but unlike classical bits they can experience a bizarre phenomenon known as superposition in which they exist in two states or more at once. Like the famous Schrödinger’s cat thought experiment, which describes a cat that is both dead and alive at the same time, particles can exist in multiple states at once. The phenomenon of superposition is at the heart of quantum computing: the fact that qubits can take on many forms simultaneously means that they have exponentially more computing power than classical bits.

Findings In this bayesian randomized clinical trial that included 403 patients and was stopped early after results from another trial were released, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority, respectively, with regard to the odds of improvement in organ support–free days within 21 days.

Objective To determine whether hydrocortisone improves outcome for patients with severe COVID-19.

Design, Setting, and Participants An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020.

Continue reading “Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial” »

A new report claims to have the scoop on Chevrolet’s in-development high-performance off-road pickup, which could be called ZR2 instead of ZRX.

Providence, R.I. — The federal government has told states to prepare for a coronavirus vaccine to be ready to distribute by Nov. 1.

The timeline raised concern among public health experts about an “October surprise” — a vaccine approval driven by political considerations ahead of a presidential election, rather than science.

In a letter to governors dated Aug. 27, Robert Redfield, director of the U.S. Centers for Disease Control and Prevention, said states “in the near future” will receive permit applications from McKesson Corp., which has contracted with CDC to distribute vaccines to places including state and local health departments and hospitals.

Medical experts say coronavirus COVID-19 and Ebola outbreaks show that robotic medicine can help fight infectious disease, but the goal needs to be applications in everyday health care.

When we came out of the financial crisis of 2008, cloud computing kicked into high gear and started to become a pervasive, transformational technology. The current COVID-19 crisis could provide a similar inflection point for AI applications. While the implications of AI continue to be debated on the world stage, the rapid onset of a global health crisis and concomitant recession will accelerate its impact.

Times of crisis bring rapid change. Efforts to harness AI technologies to discover new drugs – either vaccine or treatment – have kicked into hyperdrive. Startups are racing to find solutions and established companies are forming partnerships with academia to find a cure. Other companies are researching existing drugs for their potential applicability. AI is proving a useful tool for dramatically reducing the time needed to identify potential drug candidates, possibly saving years of research. AI uses already put into action are screening for COVID-19 symptoms, decision support for CT scans, and automating hospital operations. A variety of healthcare functions have started to be performed by robots, from diagnosis to temperature monitoring.

Whatever the new normal becomes in the aftermath of the current crisis, it’s apparent that AI will be an even larger part of the technology landscape going forward — and not only for healthcare.

As the coronavirus spreads around the world, the urgency of being able to scale up a vaccine is even more critical.

Delays in production can occur at any point in time, from timely receipt and testing of raw materials, to characterization of the drug substance, to quality testing and release.

Automation technologies can help both speed up the manufacturing process and make the process safer and more efficient by reducing manual errors.

Authorities in Spain have invested in robots to automate the testing of citizens for the Covid-19 coronavirus.

Using the spin precession of Bose-condensed 87Rb atoms as a clock, direct measurements are made of the time required for Rb atoms to quantum tunnel through a classically impenetrable barrier.